Endonovo Therapeutics Valuation
| ENDV Stock | USD 0.0004 0.0001 20.00% |
Endonovo Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Endonovo Therapeutics from reviewing the firm fundamentals such as Current Valuation of 9.74 M, shares owned by insiders of 24.61 %, and Shares Outstanding of 194.33 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Endonovo Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Endonovo Therapeutics is based on 3 months time horizon. Increasing Endonovo Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Endonovo pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Endonovo Therapeutics. Since Endonovo Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Endonovo Pink Sheet. However, Endonovo Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.0E-4 | Real 3.84E-4 | Hype 4.62E-4 |
The intrinsic value of Endonovo Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Endonovo Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Endonovo Therapeutics helps investors to forecast how Endonovo pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Endonovo Therapeutics more accurately as focusing exclusively on Endonovo Therapeutics' fundamentals will not take into account other important factors: Endonovo Therapeutics Total Value Analysis
Endonovo Therapeutics is currently forecasted to have valuation of 9.74 M with market capitalization of 3.4 M, debt of 7.36 M, and cash on hands of 59.98 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Endonovo Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.74 M | 3.4 M | 7.36 M | 59.98 K |
Endonovo Therapeutics Investor Information
About 25.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.04. Endonovo Therapeutics last dividend was issued on the 20th of December 2019. The entity had 1:1000 split on the 20th of December 2019. Based on the key indicators related to Endonovo Therapeutics' liquidity, profitability, solvency, and operating efficiency, Endonovo Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Endonovo Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Endonovo Therapeutics has an asset utilization ratio of 3.64 percent. This indicates that the Company is making $0.0364 for each dollar of assets. An increasing asset utilization means that Endonovo Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Endonovo Therapeutics Ownership Allocation
Endonovo Therapeutics holds a total of 194.33 Million outstanding shares. Endonovo Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Endonovo Therapeutics Profitability Analysis
The company reported the previous year's revenue of 73.11 K. Net Loss for the year was (3.1 M) with profit before overhead, payroll, taxes, and interest of 58.12 K.About Endonovo Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Endonovo Therapeutics. We calculate exposure to Endonovo Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Endonovo Therapeutics's related companies.Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California. Endonovo Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Endonovo Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Endonovo Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Endonovo Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Endonovo Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Endonovo Therapeutics' revenue streams: Identify Endonovo Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Endonovo Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Endonovo Therapeutics' growth potential: Evaluate Endonovo Therapeutics' management, business model, and growth potential.
- Determine Endonovo Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Endonovo Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Endonovo Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Endonovo Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 59.8 M | |
| Retained Earnings | -56.4 M |
Additional Tools for Endonovo Pink Sheet Analysis
When running Endonovo Therapeutics' price analysis, check to measure Endonovo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Endonovo Therapeutics is operating at the current time. Most of Endonovo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Endonovo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Endonovo Therapeutics' price. Additionally, you may evaluate how the addition of Endonovo Therapeutics to your portfolios can decrease your overall portfolio volatility.